THALES
17.6.2024 09:01:34 CEST | Business Wire | Press release
To create trusted generative AI solutions, Thales’s cortAIx Lab, the most powerful integrated laboratory for critical AI in Europe, and the CEA, which is one of the world’s most innovative research organisations and is listed alongside Thales in the Clarivate Analytics Top 100 Global Innovators,1 have joined forces to focus on a range of generative AI use cases, in particular for intelligence and command applications.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240617313286/en/
Alexandre Bounouh, Director of the CEA-List Institute, specialising in smart digital systems, and Bertrand Tavernier, CTO for Thales’s Secure Communications and Information Systems business, at the signing of the partnership agreement on 30 April 2024 in Palaiseau, France. (Photo: Thales)
Bertrand Tavernier, Chief Technical Officer for Thales’s Secure Communications and Information Systems business: “This partnership with the CEA’s AI teams will combine the power of their research with our work at cortAIx, Thales’s AI accelerator, which brings together the Group’s technological expertise and deep knowledge of the defence and security sectors. Our customers — governments, armed forces, critical infrastructure operators — need trusted, sovereign generative AI solutions for their critical missions.”
Alexandre Bounouh, Director of the CEA’s List Institute, specialising in smart digital systems: “This partnership builds on the long-standing collaboration between the CEA and Thales and extends it to the sensitive issue of generative AI, combining the expertise and excellence of the CEA’s research teams in AI safety and security with cortAIx’s strengths in the strategic domain of defence and security. It will support the CEA’s mission in safety, security and artificial intelligence with our partners and all institutional and industry stakeholders in this field.”
Use cases for the armed forces
Generative AI can be developed to accelerate OODA command loops (observe, orient, decide, act) and implemented across the entire critical decision chain: sensing and data gathering, data transmission and storage, data processing and decision support.
Generative AI will serve as a trusted smart assistant for users, enabling them to dialogue easily and efficiently with complex systems with the aim of facilitating and accelerating human decision-making and the tempo of operations. For intelligence gathering, for example, multimodal generative AI will make it possible to simultaneously extract, process, correlate and interpret different types of information from multiple sources — such as the web, social media and sensors in a theatre of operations — to generate summaries and accelerate the production of reliable reports.
Thales’s cortAIx Lab and the CEA will also focus on interoperability within coalitions. To simplify communication between member states in the context of a joint operation, trusted generative AI will facilitate interaction between operators and complex systems by translating their intentions into a sequence of actions and translating technical terms into the languages of the various nations involved.
Thales, a leader in trusted AI for mission-critical systems
Thales is a major player in trusted, cybersafe, transparent, explainable and ethical AI for armed forces, aircraft manufacturers and critical infrastructure operators. In 2023, the Group was Europe’s top patent applicant in the field of AI for mission-critical systems. It has more than 600 AI experts and hosts around 100 PhD students every year in AI at cortAIx, Thales’s AI accelerator in the field of research (cortAIx Lab), systems (cortAIx Factory for decision support systems) and sensors (cortAIx Sensors for sonar, radar, radio and optronics). Thanks to cortAIx and its network of world-class industry, start-up and academic partners, Thales is building AI into more than 100 of its products and services. Benefiting from the most advanced sensor and system technologies, these AI capabilities cover the full spectrum of needs in defence, aviation, space, cybersecurity and digital identity. Trusted AI is designed to meet the specific security and sovereignty needs of Thales’s customers. It brings greater efficiency to data analysis and decision support and speeds up the detection, identification and classification of objects of interest and target scenes, while taking account of specific constraints such as cybersecurity, embeddability and frugality in critical environments.
CEA, a key player in trusted AI for mission-critical systems
In the field of artificial intelligence, the CEA is uniquely positioned across the entire AI value chain, with skills ranging from algorithms and software development tools to computing architectures and microelectronics. The hardware and software solutions developed by the CEA with its academic and industry partners are aimed at applications where AI quality and performance are critical. They include sovereign applications for which the CEA is its own customer (cybersecurity, defence, energy) and industrial applications to which the CEA contributes its expertise.
The CEA has developed high-level expertise in AI technologies, enabling the agency to support its industry partners in the development of innovative solutions. At its CEA-List Institute specialising in smart digital systems, the CEA focuses its research on the development of high-performance, trusted and sovereign models.
Working with Thales, the CEA teams will be applying their expertise more specifically to develop LLMs (large language models) and VLMs (vision language models) for the sectors and use cases targeted by Thales.
About Thales Thales (Euronext Paris: HO) is a global leader in advanced technologies specialized in three business domains: Defence & Security, Aeronautics & Space, and Cybersecurity & Digital identity. It develops products and solutions that help make the world safer, greener and more inclusive. The Group invests close to €4 billion a year in Research & Development, particularly in key innovation areas such as AI, cybersecurity, quantum technologies, cloud technologies and 6G. Thales has close to 81,000 employees in 68 countries. In 2023, the Group generated sales of €18.4 billion. |
About CEA
The CEA is a major research organisation working in the best interests of the French State, its economy and citizens. Thanks to its strong roots in fundamental research, it is able to provide tangible solutions to meet their needs in four key fields: low-carbon energy, digital technologies, technologies for medicine of the future, defence and national security. As the world’s leading innovator among public research organisations (Clarivate 2024), the CEA acts as a catalyst and accelerator of innovation for French industry. It helps businesses in all sectors be more competitive, creating high-performance products that stand out from the crowd and developing trail-blazing solutions that lead to changes in society. The CEA deploys this dynamic in all regions of France aiding local partners to innovate themselves, thus helping to create sustainable value and jobs nationwide, tailored to meet actual industry needs. At the same time, it supports the development of its 250 start-ups, agile vectors for transferring the disruptive technology and knowledge developed at CEA laboratories to industry.
Find out more: www.cea.fr
PLEASE VISIT
Thales Group
Security
Thales
@Thalesgroup
___________________________
1 The CEA is listed with Thales in the Top 100 Global Innovators published by Clarivate Analytics: Thales listed among world’s top 100 most innovative companies for 11 time | Thales Group
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240617313286/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Brenus Pharma Presented New Preclinical and Early Clinical Data in Colorectal Cancer During AACR Immuno-Oncology Conference 202619.2.2026 08:50:00 CET | Press release
Brenus Pharma, a clinical-stage biotechnology company pioneering in vivo “off-the-shelf” immunotherapies, announced the selection of an abstract for a poster presentation at the American Association for Cancer Research Immuno-Oncology (AACRIO) annual conference (February 18-21, 2026), in Los Angeles. The poster showcases new preclinical data and early clinical insights from the company's lead candidate, STC-1010, supporting it as a promising therapeutic option for MSS, immune-cold colorectal cancer (CRC)—a major unmet clinical need. In a syngeneic CT26 model, murine STC-1010 significantly inhibits tumor growth and extends survival by 40%. New mechanistic datas reveal expansion of CD4⁺ and CD8⁺ T cells in draining lymph nodes alongside a significant humoral response compared to control, demonstrating coordinated cellular and humoral immune activation in vivo. Other findings show that dendritic cells efficiently capture STC-1010, leading to their activation as demonstrated by transcripto
ENHERTU® Type II Variation Application Validated in the EU as Post-Neoadjuvant Treatment for Patients with HER2 Positive Early Breast Cancer19.2.2026 08:30:00 CET | Press release
Based on DESTINY-Breast05 phase 3 trial results, which showed ENHERTU reduced the risk of invasive disease recurrence or death by 53% compared to T-DM1 If approved, Daiichi Sankyo and AstraZeneca’s ENHERTU has the potential to become a new standard of care in this early breast cancer setting The European Medicines Agency (EMA) has validated the Type II Variation marketing authorization application for ENHERTU® (trastuzumab deruxtecan) as a monotherapy for adult patients with HER2 positive (immunohistochemistry [IHC] 3+ or in-situ hybridization [ISH]+) breast cancer who have residual invasive disease after neoadjuvant HER2 targeted treatment. ENHERTU is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The validation confirms the completion of the application and commences the scientific review process by the EMA’s Committ
NHOA Energy Advances Delivery of the 51 MWh Broni Battery for Neoen in Italy19.2.2026 08:00:00 CET | Press release
The project confirms NHOA Energy’s long-term commitment to the Italian market NHOA Energy, global provider of utility-scale energy storage systems, is advancing the construction of the Broni Battery, a 10 MW/51 MWh project located in Broni (Pavia), Italy, executed for Neoen, one of the world’s leading independent producers of renewable energy. Civil works at the site are currently underway and advancing on schedule, with commissioning activities planned to start in late spring 2026. Once operational, the Broni Battery will provide essential flexibility services to the Italian electricity system, supporting grid stability and reliability as renewable energy penetration continues to increase. The project represents Neoen’s first battery storage asset in Italy and marks a strategic step in the company’s expansion, as it continues to grow its battery storage portfolio in key markets worldwide to support power system flexibility. The Broni Battery further strengthens NHOA Energy’s long-term
Compass Pathways Announces Pricing of $150 Million Public Offering19.2.2026 02:18:00 CET | Press release
Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation, announced today the pricing of its public offering of 17,500,000 American Depositary Shares (“ADSs”) at a public offering price of $8.00 per ADS, each representing one ordinary share, and in lieu of ADSs, to certain institutional investors, pre-funded warrants to purchase up to 1,250,000 ADSs at a public offering price of $7.9999 per pre-funded warrant. In addition, Compass Pathways has granted the underwriters a 30-day option to purchase up to an additional 2,812,500 ADSs at the public offering price, less the underwriting discounts and commissions. All of the securities are to be sold by Compass Pathways. The offering is expected to close on or about February 20, 2026, subject to the satisfaction of customary closing conditions. The gross proceeds to Compass Pathways from the offering, before deducting underwriting discounts and commissions and other est
Andersen Consulting udvider sine kompetencer inden for ledelsesrekruttering med Lansdowne Executive Search18.2.2026 17:08:00 CET | Pressemeddelelse
Andersen Consulting styrker sin humancapital-praksis gennem en samarbejdsaftale med Lansdowne Executive Search, der er en Dublin-baseret virksomhed med speciale i lederrekruttering, midlertidige ledelser og bestyrelsesudnævnelser. Lansdowne Executive Search er en irisk-ejet virksomhed, der blev grundlagt i 2015, og som tilbyder C-level-ledelsesekruttering, deltidsledere og bestyrelsesplaceringer. Som en partnerdrevet boutique-virksomhed er Lansdowne kendt for, at seniorledelsen er tæt involveret i alle kundeprojekter. Virksomheden hjælper kunder med at navigere i komplekse ledelsesovergange og vækststrategier på tværs af en bred vifte af sektorer, herunder finans, byggeindustrien, nonprofit, landbrug, videregående uddannelse, den offentlige sektor samt teknologi, medier og telekommunikation. "God ledelse er afhænger af situationen, og det kræver forståelse af langt mere end blot et CV," sagde Tom Keane, der er partner hos Lansdowne Executive Search. "Samarbejdet med Andersen Consulting
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom